Skip to content

Midodrine and refractory gastroesophageal disease

The therapeutic effect of Midodrine in patients with refractory gastro esophageal reflux disease: a randomized double-blind clinical trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT201402274226N2
Enrollment
60
Registered
2014-04-04
Start date
2014-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroesophageal reflux disease. Gastro- oesophageal reflux disease

Interventions

Intervention 1: Midodrine, tablet 5 mg, 3 timesper day for one month. Intervention 2: Midodrine, tablet 2.5mg, 3 times per day for one month. Intervention 3: Placebo, tablet, 3 times per day for one m
Treatment - Drugs
Placebo
Midodrine, tablet 5 mg, 3 timesper day for one month
Midodrine, tablet 2.5mg, 3 times per day for one month
Placebo, tablet, 3 times per day for one month

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age more than 18 and below 65; presence of at least one symptom compatible compatible with GERD including epigastric or retrosternal burning sensation, regurgitation, or acid taste in the mouth; lack of response to the proper consumption of pantoprazole 40 mg twice daily for a minimum of one month. Exclusion criteria: dominant symptom of dysphagia; history of surgery of the upper GI system; concomitant GI diseases such as NET, malignancy, peptic ulcer disease; presence of other diseases like hypertension, cardiovascular diseases, history of urinary retention, hypersensitivity to midodrine, leg cramp or vascular insufficiency in the abdomen or legs, acute or chronic renal dysfunction with GFR < 50%, thyroid disease, diabetes mellitus, pheochromocytoma, liver cirrhosis, asthma or COPD; use of medications affecting lower esophageal sphincter such as theophylline, beta blockers, NSAIDs, steroids, bronchodilators; antihistamine taking; pregnancy and lactation; psychiatric disorders or use of antidepressive agents; current smoker; alcohol consumption; use of narcotics or illicit drugs; history of glaucoma.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Symptom severity. Timepoint: Weekly. Method of measurement: Visual scale 0-10.;Quality of life. Timepoint: Every 2 weeks. Method of measurement: GERD quality of life standardized qustionnaire.

Secondary

MeasureTime frame
Lower esophageal sphincter pessure. Timepoint: One month. Method of measurement: Mannometry.;Esophageal residual acid reflux. Timepoint: Monthly. Method of measurement: pH meter.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholam Reza Sivandzadeh

Gastroenterohepatology research center

ghsivand@sums.ac.ir ; grc@sums.ac.ir+98 71 1647 3236

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026